These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30704943)

  • 1. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
    Tournier A; Khemis A; Maccari F; Reguiai Z; Bégon E; Fougerousse AC; Amy de la Breteque M; Beneton N; Parier J; Boyé T; Avenel-Audran M; Girard C; Pallure V; Perrot JL; Bastien M; Mahé E; Beauchet A;
    Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
    Erduran F; Emre S; Hayran Y; Adışen E; Polat AK; Üstüner P; Öztürkcan S; Öztürk P; Ermertcan AT; Selçuk LB; Aksu EK; Akbaş A; Kalkan G; Demirseren D; Kartal SP; Topkarcı Z; Kılıç A; Yaldız M; Aytekin S; Hızlı P; Gharehdaghi S; Borlu M; Işık L; Botsalı BR; Solak EÖ; Albayrak H; Gönülal M; Balcı DD; Polat M; Daye M; Ataseven A; Yıldız S; Özer İ; Zorlu Ö; Doğan S; Erdemir VA; Dikicier BS
    Arch Dermatol Res; 2024 May; 316(6):278. PubMed ID: 38796658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
    Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
    Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
    Singh SK; Singnarpi SR
    Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M; Chams-Davatchi C; Hemami MR; Fateh S
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
    Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial.
    El-Komy MHM; Sayed KS; Gawish G; Elaguizy MM; Azzazi Y
    Clin Exp Dermatol; 2024 Aug; 49(9):1029-1035. PubMed ID: 38469732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF; Chen JS; Gu J; Xu JH; Jin HZ; Pang XW; Wang G; Yu C; Song ZQ; Guo ZP; Li W; Lai W; Cui PG; Chen M; Fang H; Lyu CZ; Li YZ; Sun Q; Xie HF; Liu XM; Gao XH; Shi YL; Zhao NQ; Zhang W; Zheng M
    Arch Dermatol Res; 2020 Aug; 312(6):437-445. PubMed ID: 31873772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
    Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS;
    JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India.
    Sandhu K; Kaur I; Kumar B; Saraswat A
    J Dermatol; 2003 Jun; 30(6):458-63. PubMed ID: 12810993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
    N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study.
    Shah S; Nikam B; Kale M; Jamale V; Chavan D
    Dermatol Ther; 2021 Jan; 34(1):e14650. PubMed ID: 33296549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry.
    van Geel MJ; Oostveen AM; Hoppenreijs EP; Hendriks JC; van de Kerkhof PC; de Jong EM; Seyger MM
    J Dermatolog Treat; 2015 Oct; 26(5):406-12. PubMed ID: 25485870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal.
    Tsakok T; Jabbar-Lopez ZK; Smith CH
    Br J Dermatol; 2018 Jul; 179(1):50-53. PubMed ID: 29399784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.